Popular Blood Pressure Drug Going Generic

Friday, 27 Jun 2014 08:40 AM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
India's Ranbaxy Laboratories Ltd has received approval from the U.S. Food and Drug Administration (FDA) to launch a cheaper copy of Novartis AG's blood pressure pill Diovan, bolstering its outlook after a raft of regulatory bans for poor production quality at its India facilities dented investor sentiment.

Ranbaxy, which is in the process of being acquired by Indian drugmaker Sun Pharmaceutical Industries Ltd for $3.2 billion, will be the first rival drugmaker to launch a copy of Diovan in the United States and will be entitled to six months of exclusivity to sell it.

The drug, whose chemical name is valsartan, should add about $200 million to Ranbaxy's sales and $100 million to its profit after tax during the exclusive sale period, said Praful Bohra, a senior research analyst at Mumbai-based brokerage Nirmal Bang.
 
Swiss firm Novartis's once-best selling drug Diovan lost patent protection in September 2012, but it has been spared generic competition because Ranbaxy, which holds the right to launch the first generic of Diovan, was struggling with quality control issues at its manufacturing sites.
 
The FDA has banned all of Ranbaxy's India-based plants under a wider scrutiny of the country's $15 billion pharmaceutical industry, which is the largest supplier of medicines to the United States.

Novartis will continue to market both its branded and generic versions of Diovan, Dermot Doherty, a spokesman for the company in Zurich, said in statement.

Novartis earned about $100 million each month for the last 20 months without a generic rival of Diovan in the U.S. market, said Angel Broking's pharmaceutical analyst Sarabjit Kour Nangra.

Ranbaxy could not manufacture the pharmaceutical ingredient required for Diovan generic because of bans on its plants, but some analysts said the company could have sourced the raw materials from another domestic manufacturer.
 

The finished dose of the drug will be made at Ranbaxy’s New Jersey-based Ohm Labs unit, which is the only company-owned plant allowed to make drugs for the United States, Ranbaxy said on Friday.

Bill Winter, a vice president at Ohm Labs, said in a statement the Diovan generic would be launched "as soon as sufficient supplies are manufactured to meet the needs of the market."
 

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Bird Flu Could 'Make Ebola Look Like a Picnic'

Sunday, 23 Nov 2014 10:09 AM

The next Ebola or the next SARS. Maybe even the next HIV. Even before the Ebola epidemic in West Africa is brought under . . .

Pope Meets With Autistic Kids

Sunday, 23 Nov 2014 10:01 AM

Pope Francis tenderly embraced children with autism spectrum disorders, some of whom avoided meeting his gaze, during an . . .

Female Bosses Prone to Depression: Study

Friday, 21 Nov 2014 23:11 PM

Being the boss at work seems to raise the odds for symptoms of depression among women, but not men, a new study finds.  . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved